Published on January 5, 2015

With few days left for 2014, the yearly calculation has begun for pharma sector. The overall year remained mixed for Indian pharma companies. With bitter experiences from USFDA, several sanctions, big acquisitions and expansion of Indian pharma companies in foreign land remained some of the major highlights for this industry in 2014.

Several Indian drug companies remained under scanner of US and European drug regulation charges. Many drugs were rejected as the manufacturing units could not come out clean with international norms. Other major companies which faced ban by US were Wockhardt, Dr Reddy’s laboratories and IPCA labs. On other hand domestic government also wanted to put on hold on pricing of the essential drugs including diabetes, common cold and cough and cancer drugs.

There was major takeover of Ranbaxy by an Indian firm itself Sun pharma, leading to become the fifth largest drug maker company in the world. There were other major tie ups among the companies to develop other generic and medicines for disease like AIDS. Aurbindo, Cipla and Emcure were among seven such global companies which signed sub-licensing agreements with UN backed medicines Patent Pool.   

The healthcare industry remained on toes throughout this year with a lot of development s happening in this year. In the last three months there has been significant decline in the chemical prices due to plunging of crude rates. These prices has lowered to a greater extent making way for significant decline in the raw material cost in pharma industry